Amplius Wealth Advisors LLC Acquires 20,911 Shares of Pfizer Inc. (NYSE:PFE)

Amplius Wealth Advisors LLC increased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 80.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 46,823 shares of the biopharmaceutical company's stock after purchasing an additional 20,911 shares during the period. Amplius Wealth Advisors LLC's holdings in Pfizer were worth $1,242,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in PFE. Cove Private Wealth LLC raised its stake in shares of Pfizer by 693.5% during the fourth quarter. Cove Private Wealth LLC now owns 92,280 shares of the biopharmaceutical company's stock valued at $2,448,000 after purchasing an additional 80,650 shares in the last quarter. FLC Capital Advisors lifted its stake in shares of Pfizer by 22.8% in the 4th quarter. FLC Capital Advisors now owns 47,611 shares of the biopharmaceutical company's stock worth $1,263,000 after acquiring an additional 8,839 shares during the period. SFG Wealth Management LLC. acquired a new position in shares of Pfizer during the fourth quarter valued at approximately $228,000. Baugh & Associates LLC raised its holdings in Pfizer by 17.6% during the fourth quarter. Baugh & Associates LLC now owns 194,168 shares of the biopharmaceutical company's stock worth $4,970,000 after purchasing an additional 29,025 shares in the last quarter. Finally, AHL Investment Management Inc. lifted its position in Pfizer by 0.6% in the fourth quarter. AHL Investment Management Inc. now owns 85,437 shares of the biopharmaceutical company's stock worth $2,267,000 after purchasing an additional 550 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analyst Weigh In

PFE has been the topic of several research analyst reports. Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Citigroup started coverage on shares of Pfizer in a research note on Friday, October 25th. They issued a "neutral" rating and a $30.00 price objective on the stock. Bank of America restated a "neutral" rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $32.00.

Pfizer Stock Up 1.2 %

NYSE:PFE traded up $0.33 on Tuesday, hitting $26.63. 39,583,856 shares of the company's stock traded hands, compared to its average volume of 34,055,406. The firm has a 50-day moving average price of $26.08 and a 200-day moving average price of $27.98. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market cap of $150.89 billion, a PE ratio of 35.98, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business's revenue was up 31.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.17) EPS. Equities analysts anticipate that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This is a positive change from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.46%. Pfizer's dividend payout ratio is 227.03%.

Insider Activity at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the company's stock in a transaction dated Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.